Opinion|Podcasts|November 6, 2023

Tailoring Therapies in Community Acquired Pneumonia in the Inpatient Setting

An expert in infectious diseases shares treatment considerations and clinical strategies for the management of community acquired pneumonia (CAP).

0:00 Burden of Community Acquired Pneumonia (CAP)

3:11 Strategies for Approaching Treatment Selection of CAP

6:00 Understanding Multidrug-Resistant Pathogens (MDR) and Antimicrobial Stewardship in CAP

10:52 Unmet Needs and Key Takeaways in CAP Management


Related to this article

New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
REMAP-CAP and the Tamiflu “Pre-Release”: A Set-Up for Disaster
Preliminary REMAP-CAP data suggesting oseltamivir may increase mortality in critically ill ICU influenza patients has sparked polarized reactions, but clinicians should await the full peer-reviewed manuscript before drawing broad conclusions, since the signal comes from a narrow, severely ill population and may reflect a therapeutic window effect rather than a blanket lack of efficacy.
GSK's mRNA Influenza Vaccine Moves to Phase 3 Trial
GSK will advance its investigational mRNA seasonal flu vaccine candidate, which targets both hemagglutinin and neuraminidase, into a phase 3 trial in September 2026 after the shot outperformed licensed flu vaccines in a phase 2 study.